IMLYGIC

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug IMLYGIC contains one active pharmaceutical ingredient (API):

1	Talimogene laherparepvec UNII 07730V90L6 - TALIMOGENE LAHERPAREPVEC
	Talimogene laherparepvec is an oncolytic immunotherapy that is derived from HSV-1. Talimogene laherparepvec has been modified to replicate within tumours and to produce the immune stimulatory protein human GM-CSF. Talimogene laherparepvec causes the death of tumour cells and the release of tumour-derived antigens.
	Read more about Talimogene laherparepvec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMLYGIC Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1708590, 1708602
FI	Lääkealan turvallisuus- ja kehittämiskeskus	050826, 475527
FR	Base de données publique des médicaments	65763328, 67792809
GB	Medicines & Healthcare Products Regulatory Agency	348715, 348717
IL	מִשְׂרַד הַבְּרִיאוּת	8509, 8510
IT	Agenzia del Farmaco	044653018, 044653020
LT	Valstybinė vaistų kontrolės tarnyba	1079249, 1079250
NL	Z-Index G-Standaard, PRK	130346, 130354
PL	Rejestru Produktów Leczniczych	100362830, 100362846
US	FDA, National Drug Code	55513-078, 55513-079